Press Releases

Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

March 4, 2021

Tags |  Product

Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

March 3, 2021

Tags |  Product

- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ --  Eli Lilly and Company  (NYSE: LLY) and  Incyte  (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a

Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19

February 26, 2021

Tags |  Product

INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions

February 25, 2021

Tags |  Product

COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.

Lilly to Participate in Cowen Health Care Conference

February 24, 2021

Tags |  Financial

INDIANAPOLIS , Feb. 24, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41 st Annual Health Care Conference on Thursday, March 4, 2021 . Daniel Skovronsky , M.D., Ph.D., Lilly 's Chief Scientific Officer and President of Lilly Research Laboratories

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

February 18, 2021

Tags |  Corporate

- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications - Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory,

Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program

February 17, 2021

Tags |  Product

In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent) INDIANAPOLIS , Feb. 17, 2021 /PRNewswire/ -- Tirzepatide led to significant A1C and body weight reductions from

Kimberly H. Johnson Elected to Lilly Board of Directors

February 17, 2021

Tags |  Corporate

INDIANAPOLIS , Feb. 17, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021 . As a member of Lilly 's board, she will serve on both the Compensation Committee and the Ethics and Compliance

Lilly To Participate in SVB Leerink Global Healthcare Conference

February 11, 2021

Tags |  Financial

INDIANAPOLIS , Feb. 11, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 . Ilya Yuffa , Lilly senior vice president and president of Lilly Bio-Medicines, will participate in a fireside

Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19

February 9, 2021

Tags |  Product

- Bamlanivimab and etesevimab administered together authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 - More than 250,000 doses manufactured throughout Q1 2021; up to 1 million doses by mid-2021 - FDA